Lower Grade Glioma
Conditions
Keywords
Lower grade glioma, Metabolomics, Tumor heterogeneity, Patient Stratification
Brief summary
The goal of this observational study is to better characterise lower-grade gliomas from a molecular and metabolic point of view, so to identify further subgroups of these tumours with different behaviour and, possibly, different treatment susceptibility. Participants of prospective metabolic cohort will be subjected to routine treatment, part of the exceeding tutor material will be subjected to advanced molecular-metabolic analyses to desume their metabolic profile to be then correlated with clinical outcome (progression-free survival, overall survival, response to therapy/progression) and diagnosis (astrocytoma/oligodendroglioma and grade). Critical enzymes identified from metabolic analyses on the first cohort will be tested on a protein level on a retrospective cohort of patients previously operated and for whom fully available clinical history and pathological material is available in Institutional archive (no need for further intervention on these patients) to see if they actually correlate with clinical outcome.
Interventions
None listed
Sponsors
Università Vita-Salute San Raffaele
University of Bari
Ospedale San Paolo Bari
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Prospective Metabolic Cohort: Inclusion Criteria: * Radiological diagnosis of brain tumor compatible with lower grade glioma * Full clinical history
Exclusion criteria
* Current pregnancy or lactation * Patients not able to provide informed consent Retrospective Cohort of FFPE samples: Inclusion Criteria: * Confirmed diagnosis of lower grade glioma * Full clinical and radiological history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | (up to 180 months) | time from surgery to evidence of radiological progression at MRI |
| Overall Survival (OS) | (up to 180 months) | Time from surgery to tumor-related death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Histological-molecular diagnosis (integration of immunohistochemistry and molecular evaluation of IDH1/2, ATRX and 1p/19q chromosomal deletion) | From date of surgery to date of complete diagnosis (weeks) | Astrocytoma vs Oligodendroglioma (integration of immunohistochemistry and molecular evaluation of IDH1/2, ATRX and 1p/19q chromosomal deletion) |
| Tumor Grade at histology and molecular analysis (CDKN2A/B deletion) | From surgery to complete history-molecular diagnosis (weeks) | Tumor grade upon histology and molecular analysis (CDKN2A/B deletion) |
Countries
Italy
Contacts
Primary ContactLorenzo Bello, MD
Backup ContactDirezione Scientifica IRCCS Galeazzi-Sant'Ambrogio, Milano
Outcome results
None listed